175 related articles for article (PubMed ID: 10924649)
1. Cost effectiveness of vaccination strategies in adults without a history of chickenpox.
Smith KJ; Roberts MS
Am J Med; 2000 Jun; 108(9):723-9. PubMed ID: 10924649
[TBL] [Abstract][Full Text] [Related]
2. An economic evaluation and incremental analysis of the cost effectiveness of three universal childhood varicella vaccination strategies for Ireland.
Ahern S; Browne J; Murphy A; Teljeur C; Ryan M
Vaccine; 2024 May; 42(14):3321-3332. PubMed ID: 38609807
[TBL] [Abstract][Full Text] [Related]
3. Varicella vaccination in England and Wales: cost-utility analysis.
Brisson M; Edmunds WJ
Arch Dis Child; 2003 Oct; 88(10):862-9. PubMed ID: 14500303
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan.
Hoshi SL; Kondo M; Okubo I
Vaccine; 2017 May; 35(24):3264-3271. PubMed ID: 28479176
[TBL] [Abstract][Full Text] [Related]
5. Varicella vaccination in Italy : an economic evaluation of different scenarios.
Coudeville L; Brunot A; Giaquinto C; Lucioni C; Dervaux B
Pharmacoeconomics; 2004; 22(13):839-55. PubMed ID: 15329030
[TBL] [Abstract][Full Text] [Related]
6. The economic value of childhood varicella vaccination in France and Germany.
Coudeville L; Brunot A; Szucs TD; Dervaux B
Value Health; 2005; 8(3):209-22. PubMed ID: 15877593
[TBL] [Abstract][Full Text] [Related]
7. Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination.
Hanslik T; Boëlle PY; Schwarzinger M; Carrat F; Freedberg KA; Valleron AJ; Flahault A
Vaccine; 2003 Sep; 21(25-26):3614-22. PubMed ID: 12922090
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster.
Littlewood KJ; Ouwens MJ; Sauboin C; Tehard B; Alain S; Denis F
Clin Ther; 2015 Apr; 37(4):830-841.e7. PubMed ID: 25721380
[TBL] [Abstract][Full Text] [Related]
9. Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting?
Bilcke J; van Hoek AJ; Beutels P
Hum Vaccin Immunother; 2013 Apr; 9(4):812-22. PubMed ID: 23321955
[TBL] [Abstract][Full Text] [Related]
10. How cost effective is universal varicella vaccination in developing countries? A case-study from Colombia.
Paternina-Caicedo A; De la Hoz-Restrepo F; Gamboa-Garay O; Castañeda-Orjuela C; Velandia-González M; Alvis-Guzmán N
Vaccine; 2013 Jan; 31(2):402-9. PubMed ID: 23174195
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of varicella vaccine as post-exposure prophylaxis in Hong Kong.
Chui KS; Wu HL; You JH
Scand J Infect Dis; 2014 Jan; 46(1):27-33. PubMed ID: 24228821
[TBL] [Abstract][Full Text] [Related]
12. Health Impact and Cost-effectiveness Assessment for the Introduction of Universal Varicella Vaccination in Switzerland.
Heininger U; Pillsbury M; Samant S; Lienert F; Guggisberg P; Gani R; O'Brien E; Pawaskar M
Pediatr Infect Dis J; 2021 Jun; 40(6):e217-e221. PubMed ID: 33872276
[TBL] [Abstract][Full Text] [Related]
13. An economic analysis of the universal varicella vaccination program in the United States.
Zhou F; Ortega-Sanchez IR; Guris D; Shefer A; Lieu T; Seward JF
J Infect Dis; 2008 Mar; 197 Suppl 2():S156-64. PubMed ID: 18419391
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of varicella vaccination of healthcare workers.
Chodick G; Ashkenazi S; Livni G; Lerman Y
Vaccine; 2005 Oct; 23(43):5064-72. PubMed ID: 16046036
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness and budget impact of universal varicella vaccination in Russia.
Marijam A; Safonova E; Scherbakov M; Shpeer E; Van Oorschot D; Rudakova A; Tatochenko V; Briko N
Hum Vaccin Immunother; 2022 Nov; 18(5):2045152. PubMed ID: 35258445
[TBL] [Abstract][Full Text] [Related]
16. Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.
Damm O; Ultsch B; Horn J; Mikolajczyk RT; Greiner W; Wichmann O
BMC Public Health; 2015 Jun; 15():533. PubMed ID: 26041469
[TBL] [Abstract][Full Text] [Related]
17. Cost-benefit analysis of routine childhood vaccination against chickenpox in Taiwan: decision from different perspectives.
Hsu HC; Lin RS; Tung TH; Chen TH
Vaccine; 2003 Sep; 21(25-26):3982-7. PubMed ID: 12922134
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom.
van Hoek AJ; Melegaro A; Gay N; Bilcke J; Edmunds WJ
Vaccine; 2012 Feb; 30(6):1225-34. PubMed ID: 22119592
[TBL] [Abstract][Full Text] [Related]
19. Prevention of chickenpox in reproductive-age women: cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles.
Smith WJ; Jackson LA; Watts DH; Koepsell TD
Obstet Gynecol; 1998 Oct; 92(4 Pt 1):535-45. PubMed ID: 9764625
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of a routine varicella vaccination program for US children.
Lieu TA; Cochi SL; Black SB; Halloran ME; Shinefield HR; Holmes SJ; Wharton M; Washington AE
JAMA; 1994 Feb; 271(5):375-81. PubMed ID: 8283587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
